WJWei Jie

Wei Jie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Jie has a total of 136 co-authors. Here are the top co-authors by number of shared publications:

  • Zhihua Shen

    Department of Pathophysiology, School of Basic Medicine Sciences, Guangdong Medical University, Zhanjiang 524023, China

    16 shared publications
  • Yangyang Zhao

    Key Laboratory of Emergency and Trauma of Ministry of Education, Engineering Research Center for Hainan Biological Sample Resources of Major Diseases, the Hainan Branch of National Clinical Research Center for Cancer, the First Affiliated Hospital, Hainan Medical University, Haikou 571199, China

    11 shared publications
  • Junli Guo

    Hainan Provincial Key Laboratory for Tropical Cardiovascular Diseases Research & Institute of Cardiovascular Diseases, Hainan Medical University, Haikou, China

    10 shared publications
  • Kaijia Shi

    Key Laboratory of Emergency and Trauma of Ministry of Education, Engineering Research Center for Hainan Biological Sample Resources of Major Diseases, The Hainan Branch of National Clinical Research Center for Cancer, The First Affiliated Hospital, Hainan Medical University, Haikou 570102, China

    8 shared publications
  • Yan Chen

    Key Laboratory of Emergency and Trauma of Ministry of Education, Engineering Research Center for Hainan Biological Sample Resources of Major Diseases, the Hainan Branch of National Clinical Research Center for Cancer, the First Affiliated Hospital, Hainan Medical University, Haikou 571199, China

    8 shared publications
  • Yanping Ha

    Department of Pathology and Pathophysiology, School of Basic Medicine Sciences, Guangdong Medical University, Zhanjiang, China

    8 shared publications

Latest Publications

  • Targeting TAK1 to overcome cisplatin resistance in lung adenocarcinoma by rewiring the NF-κB and p53 signaling

    by Wenyan Lu, Kunhao Tang, Zechen Wang, Jiaqi Li, Kaijia Shi, Zhenling Wan, Zhihua Shen, Wei Jie, Shaojiang Zheng

  • Open Access

    Mechanistic insights into PFAS derivatives-induced coronary heart disease and atherosclerotic renal artery stenosis via integrated network toxicology and molecular modeling

    by Jinxuan Chai, Yan Wang, Cheng Zhang, Yuelu Wang, Ao Xue, Wei Jie

    Per- and polyfluoroalkyl substances (PFAS), such as PFHpA, PFOA, PFNA, and PFDA, are persistent environmental pollutants associated with multiple diseases. This study investigates the toxic mechanisms and pathways by which PFAS derivatives contribute to coronary artery disease (CAD) and renal arteriosclerosis. Using multiple databases, we identified toxic and disease-related targets and constructed a protein–protein interaction (PPI) network via the STRING database to analyze their interactions. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to identify relevant disease pathways. GO and KEGG results indicated significant enrichment in lipid metabolism, arteriosclerosis, cell proliferation, apoptosis, and inflammation. Molecular docking and dynamics simulations were used to evaluate the binding affinity and stability of PFAS derivatives with key targets. Core regulatory targets within the toxicity network—STAT3, MMP9, NFκB1, CASP3, AKT1, and PPARG—were found to mediate cardiotoxicity and nephrotoxicity through multiple pathways. Docking studies confirmed strong binding affinity (<-5 kcal/mol) between PFAS derivatives and these targets. Molecular dynamics simulations suggested that PFDA binds more stably to MMP9 than to other proteins. These findings indicate that PFAS derivatives may exacerbate renal and coronary arteriosclerosis by modulating lipid and arteriosclerosis signaling pathways and affecting key genes including STAT3, MMP9, and NFκB1. This study highlights potential mechanisms underlying PFAS-induced cardiovascular and renal damage.


  • Open Access

    Phenotypic Age Acceleration as a Mediator in Thyroid Hormone–Related Cardiovascular Risk Among the Elderly

    by Minmin Wen, Yanjun Hou, Kaijia Shi, Jiaxin Zuo, Cheng Zhang, Shuya Zhang, Zhihua Shen, Wei Jie

    Background: The association between thyroid hormones and cardiovascular disease (CVD) has been widely examined; however, the role of biological aging in this relationship remains unclear. This study systematically investigates the mediating role of phenotypic age acceleration (PhenoAgeAccel) in the relationship between thyroid hormones and CVD. Methods: The data were sourced from the 2007–2010 cycles of the National Health and Nutrition Examination Survey (NHANES). Analyses included logistic regression, linear regression, restricted cubic splines, subgroup analyses, and mediation analysis to assess the role of PhenoAgeAccel. Results: Among participants aged ≥ 60 years, elevated free triiodothyronine (FT3) concentrations were linked to a reduced risk of CVD (adjusted odds ratio [aOR] = 0.483; 95% CI: 0.273–0.856; p = 0.013). Similarly, total triiodothyronine (TT3) levels were associated with a decreased CVD risk in those aged 60 and above (aOR = 0.988; 95% CI: 0.980–0.995; p = 0.013). Mediation analysis showed that PhenoAgeAccel mediated 21.13% of the FT3–CVD association and 23.41% of the TT3–CVD association in older adults. Conclusion: This study identifies an age‐dependent relationship between FT3, TT3, and CVD and reveals that PhenoAgeAccel partially mediates this association. These findings suggest that interventions targeting thyroid function and biological aging may offer novel strategies for CVD prevention and management in older populations.

  • Open Access

    Dendrobin A inhibits gastric cancer: Mechanistic insights supported by integrated evidence

    by Yonghao Fan, Yan Chen, Wenyan Lu, Kaijia Shi, Yangyang Zhao, Cheng Zhang, Zhihua Shen, Shaojiang Zheng, Wei Jie


  • Biomimetic nanoplatforms for combined DDR2 inhibition and photothermal therapy in dense breast cancer treatment

    by Yan Chen, Ye Yu, Yonghao Fan, Wenyan Lu, Yunpeng Wei, Julan Wu, Banzhan Ruan, Zhenling Wan, Yangyang Zhao, Keping Xie, et al.


  • Open Access

    Diabetes Advances Cardiomyocyte Senescence Through Interfering Rnd3 Expression and Function

    by Linxu Wu, Xinglin Zhu, Shanshan Pan, Yan Chen, Cai Luo, Yangyang Zhao, Jingci Xing, Kaijia Shi, Shuya Zhang, Jiaqi Li, et al.

    Rnd3 is a small Rho‐GTPase that has been implicated in various cardiovascular diseases. Yet, its role in diabetes‐induced cardiomyocyte senescence remains unknown. Here we tested the role of Rnd3 in cardiomyocyte senescence and diabetic cardiomyopathy (DCM). The expression of Rnd3 was found to be reduced in peripheral blood mononuclear cells from diabetic patients and correlated negatively with age but positively with cardiac function. In 96‐week‐old Sprague Dawley (SD) rats, cardiac function was impaired, accompanied by an increased number of SA‐β‐gal‐positive cells and elevated levels of the senescence‐associated secretory phenotype (SASP) related factors, compared to those of 12‐week‐old rats. Diabetes and high glucose (HG, 35 mmol/L D‐glucose) suppressed Rnd3 expression in cardiomyocytes and induced cardiomyocyte senescence. The deficiency of Rnd3 exacerbated cardiomyocyte senescence in vitro and in vivo. MicroRNA sequencing in AC16 cells identified a conserved miR‐103a‐3p (present in humans and rats) as a key HG‐upregulated microRNA that bound to the Rnd3 3′‐UTR. In cultured cardiomyocytes, miR‐103a‐3p inhibitors antagonized HG‐induced cardiomyocyte senescence dependent on Rnd3 expression. Treatment with AAV9 vectors carrying miR‐103a‐3p sponges and Rnd3 ‐overexpressing plasmids alleviated cardiomyocyte senescence and restored cardiac function in diabetic SD rats. HG stimulation increased STAT3 (Tyr705) phosphorylation and promoted its nuclear translocation in H9C2 cells, an effect exacerbated by Rnd3 knockout. Mechanistically, Rnd3 interacted with p‐STAT3 in the cytoplasm, facilitating proteasome‐mediated ubiquitination and p‐STAT3 degradation. The STAT3 inhibitor S3I‐201 blocked HG‐induced STAT3 activation and mitigated cardiomyocyte senescence. These findings suggest that diabetes induces cardiomyocyte senescence via the miR‐103a‐3p/Rnd3/STAT3 signaling pathway, highlighting a potential therapeutic target for DCM.


  • Open Access

    Establishment of a nomogram model based on immune-related genes using machine learning for aortic dissection diagnosis and immunomodulation assessment

    by Yanjun Hou, Yangyang Zhao, Zhensu Shi, Yipeng Pan, Kaijia Shi, Chaoyang Zhao, Shengnan Liu, Yongkun Chen, Lini Zhao, Jizhen Wu, et al.

    The clinical manifestation of aortic dissection (AD) is complex and varied, making early diagnosis crucial for patient survival. This study aimed to identify immune-related markers to establish a nomogram model for AD diagnosis. Three datasets from GEO—GSE52093, GSE147026 and GSE153434—were combined and used for identification of immune-related causative genes using weighted gene co-expression network analysis, and 136 immune-related genes were obtained. Then, 15 pivotal genes were screened by the protein-protein interaction network. Through machine learning including the Least Absolute Shrinkage and Selection Operator algorithm, random forest algorithm, and multivariate logistic regression, four key feature genes were obtained—CXCL1, ITGA5, PTX3, and TIMP1—and the diagnostic scores based on these four genes were proved to be effective in distinguishing between AD patients and healthy donors. External dataset (GSE98770 and GSE190635) validation revealed this nomogram displayed strong predictive significance. Further analysis revealed that these genes are related with neutrophils, resting NK cells, resting mast cells, activated mast cells, activated dendritic cells, central memory CD4 T cells, γδ T cells, natural killer T cells, and myeloid-derived suppressor cells in AD. Finally, these four genes were validated to be upregulated in AD patients' tissue and serum samples compared with controls. These results suggest that this nomogram model, using machine learning identified four immune-related genes CXCL1, ITGA5, PTX3, and TIMP1, displays superior diagnostic ability in distinguishing AD and healthy individuals, and immune cells commonly associated with these hub genes may be therapeutic targets for AD.


  • Open Access

    Identification of potential therapeutic targets for nonischemic cardiomyopathy in European ancestry: an integrated multiomics analysis

    by Kaijia Shi, Xu Chen, Yangyang Zhao, Peihu Li, Jinxuan Chai, Jianmin Qiu, Zhihua Shen, Junli Guo, Wei Jie

    Nonischemic cardiomyopathy (NISCM) is a clinical challenge with limited therapeutic targets. This study aims to identify promising drug targets for NISCM. We utilized cis-pQTLs from the deCODE study, which includes data from 35,559 Icelanders, and SNPs from the FinnGen study, which includes data from 1,754 NISCM cases and 340,815 controls of Finnish ancestry. Mendelian randomization (MR) analysis was performed to estimate the causal relationship between circulating plasma protein levels and NISCM risk. Proteins with significant associations underwent false discovery rate (FDR) correction, followed by Bayesian colocalization analysis. The expression of top two proteins, LILRA5 and NELL1, was further analyzed using various NISCM datasets. Descriptions from the Human Protein Atlas (HPA) validated protein expression. The impact of environmental exposures on LILRA5 was assessed using the Comparative Toxicogenomics Database (CTD), and molecular docking identified the potential small molecule interactions. MR analysis identified 255 circulating plasma proteins associated with NISCM, with 16 remaining significant after FDR correction. Bayesian colocalization analysis identified LILRA5 and NELL1 as significant, with PP.H4 > 0.8. LILRA5 has a protective effect (OR = 0.758, 95% CI, 0.670–0.857) while NELL1 displays the risk effect (OR = 1.290, 95% CI, 1.199–1.387) in NISCM. Decreased LILRA5 expression was found in NISCM such as diabetic, hypertrophic, dilated, and inflammatory cardiomyopathy, while NELL1 expression increased in hypertrophic cardiomyopathy. HPA data indicated high LILRA5 expression in neutrophils, macrophages and endothelial cells within normal heart and limited NELL1 expression. Immune infiltration analysis revealed decreased neutrophil in diabetic cardiomyopathy. CTD analysis identified several small molecules that affect LILRA5 mRNA expression. Among these, Estradiol, Estradiol-3-benzoate, Gadodiamide, Topotecan, and Testosterone were found to stably bind to the LILRA5 protein at the conserved VAL-15 or THR-133 residues in the Ig-like C2 domain. Based on European Ancestry Cohort, this study reveals that LILRA5 and NELL1 are potential therapeutic targets for NISCM, with LILRA5 showing particularly promising prospects in diabetic cardiomyopathy. Several small molecules interact with LILRA5, implying potential clinical implication.